本研究旨在评价冷重组甲型流感/朝鲜(CR-59,H3N2)疫苗对婴儿在安全性和抗原性,并确定抗相应的甲型流感病毒的母体抗体是否抑制疫苗的感染性,同时还测定了疫苗病毒鼻内接种引起50%婴儿感染所需的剂量.给24名5～13月龄的婴儿鼻内接种甲 This study aimed to evaluate the safety and antigenicity of cold-adapted influenza A / North Korea (CR-59, H3N2) vaccine against infants and to determine whether maternal antibodies against the corresponding influenza A virus would inhibit the vaccine’s infectivity, The dose required for intranasal vaccination of the vaccine virus causing 50% of the infants was determined, and 24 infants in the 5-13 month age group were given intranasal inoculation